4.7 Review

Developing an effective treatment algorithm for rheumatoid arthritis

期刊

RHEUMATOLOGY
卷 51, 期 -, 页码 V48-V54

出版社

OXFORD UNIV PRESS
DOI: 10.1093/rheumatology/kes122

关键词

biologic agents; clinical remission; rheumatoid arthritis treatment

资金

  1. F. Hoffmann-La Roche Ltd.
  2. Roche
  3. UCB
  4. Abbott
  5. Merck
  6. Pfizer
  7. BMS

向作者/读者索取更多资源

RA is defined by the interrelated triad of disease activity, joint damage and disability. Although disease activity and its associated disability are reversible, joint damage and its associated disability are not. Thus, an important goal of RA therapy is to maximally reduce disease activity and thereby mitigate the accumulation of irreversible joint damage. Treatment for patients with RA should be initiated early and aggressively, with frequent assessments and a goal of achieving remission as quickly as possible after treatment initiation. We propose a treatment algorithm that recommends early and aggressive therapy with high-dose MTX therapy (15-25 mg/week), which may include moderate doses of glucocorticoids. The goal is to achieve low disease activity (determined by a composite measure that includes joint counts) within 3-6 months. If low disease activity is not achieved by 6 months, another conventional DMARD or a biologic agent should be added to the treatment regimen or patients should be switched to another DMARD plus a glucocorticoid. Once low disease activity is achieved, the treatment goal for the ensuing 3-6 months becomes disease remission.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据